SHIP1 Modulators for Immune Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective small molecule SHIP1 modulators for treating immune and hematopoietic disorders, and there is a need for pharmaceutical compositions and methods to target SHIP1 for diseases benefiting from its modulation.
Innovation Solution
Development of compounds of formula (I) that act as SHIP1 modulators, including agonists or antagonists, for use in pharmaceutical compositions to treat autoimmune, inflammatory, and neoplastic diseases by administering an effective amount to modulate SHIP1 activity in mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PI3K pathway inhibition is used to treat inflammatory and immune disorders, then cellular PIP3 levels are reduced, but off-target effects and toxicity occur due to the broad role of PI3K in multiple cell types
Solution Approach 1:
The patent applies local quality by designing SHIP1 modulators that specifically target immune and hematopoietic cells where SHIP1 is expressed, while leaving other cell types unaffected. This cell-type-specific approach reduces off-target toxicity while maintaining therapeutic efficacy in treating inflammatory and immune disorders.
Solution Approach 2:
The patent uses SHIP1 as an intermediary target between PI3K and downstream effectors. By modulating SHIP1 phosphatase activity rather than directly inhibiting PI3K, the patent achieves PIP3 level regulation with greater selectivity and reduced systemic toxicity compared to broad PI3K pathway inhibition.
2Reliability
If broad PI3K pathway inhibition is implemented, then inflammatory and immune disorders are treated, but specificity to immune and hematopoietic cells is lost
Solution Approach 1:
The patent exploits the local quality difference in SHIP1 expression patterns across cell types. Since SHIP1 is predominantly expressed in immune and hematopoietic cells, modulators of this enzyme achieve cell-type-specific therapeutic effects, sparring non-immune tissues from off-target effects while treating inflammatory and immune disorders.
3Adaptability or versatility
If small molecule SHIP1 modulators are developed, then targeted therapy for immune and hematopoietic disorders is achieved, but effective compounds with desired pharmacological properties are lacking
Solution Approach 1:
The patent employs parameter changes by systematically modifying chemical structures of small molecule SHIP1 modulators to optimize their pharmacological properties. This includes adjusting molecular weight, lipophilicity, hydrogen bonding capacity, and structural features to achieve desired absorption, distribution, metabolism, and excretion (ADME) characteristics while maintaining target specificity.
Data Source
AI summary
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.